The bipartisan, bicameral legislation reauthorizes the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for five years
WASHINGTON – Arizona senior Senator Kyrsten Sinema cosponsored the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act – bipartisan, bicameral legislation reauthorizing the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for five years to allow for greater flexibility in providing access to lifesaving screening, diagnostic, and treatment services and continue its innovative work aimed to reduce disparities and advance health equity in breast and cervical cancer.
The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides breast and cervical cancer screenings, diagnostic tests, and treatment referral services to women who are limited-income, underserved, underinsured, or uninsured, and do not qualify for Medicaid. The SCREENS for Cancer Act would reauthorize NBCCEDP through 2028.
“Our legislation ensures the National Breast and Cervical Cancer Early Detection Program may continue providing lifesaving breast and cervical cancer screenings, diagnostic, and treatment services to women in underserved communities,” said Sinema.
Early detection of breast and cervical cancer through screening can improve survival and reduce mortality by finding cancer at an early stage when treatment is more effective and less expensive. However, research has shown there are many barriers to cancer screening for people with limited income, including access to providers and facilities, costs of screening and care, lack of knowledge and understanding about the role of screening, as well as barriers like time off work and access to childcare. Unfortunately, people who are uninsured and underinsured have lower breast and cervical cancer screening rates, resulting in a greater risk of being diagnosed at a later, more advanced stage of disease.
Since the program’s inception in 1991, NBCCEDP has provided over 16.1 million screening exams to more than 6.2 million eligible people, detecting 77,968 invasive breast cancers and 24,656 premalignant breast lesions, as well as 5,220 invasive cervical cancers, and 242,261 premalignant cervical lesions, of which 38% were high grade.
In 2024, an estimated 310,720 women in the U.S. will be diagnosed with invasive breast cancer, and 42,250 will die from the disease. Additionally, an estimated 13,820 people will be diagnosed with invasive cervical cancer, and 4,360 will die from the disease.
The SCREENS for Cancer Act does not require any additional funding and has no score. Importantly, early detection of breast and cervical cancer through screening can improve survival and reduce mortality by finding cancer at an early stage when treatment is more effective and less expensive. Currently, the U.S. spends approximately $30 billion annually on breast cancer treatments. This could be significantly reduced if more women receive their annual screenings, and the disease is caught early. For cervical cancer, the current expenditure is approximately $12 billion annually.